ABVC BioPharma Announces Vitargus® Phase II Study Plan Approved by HREC in Australia

FREMONT, CA, Oct. 05, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that its Vitrargus Phase II study plan was approved by the Australian Bellberry Human Research Ethics Committee (HREC) on September 29, 2022.